Tc 99m ciprofloxacin

Drug Profile

Tc 99m ciprofloxacin

Alternative Names: INFECTON

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator BTG; St. Bartholomews Hospital
  • Developer DRAXIS Specialty Pharmaceuticals
  • Class Heavy metals; Radiopharmaceuticals
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging
  • 29 Mar 2006 Enrolment has been completed in phase II studies in patients with soft tissue infections and in patients with osteomyelitis; enrolment is near completion in a phase II study in patients with diabetic foot ulcer, and is underway in patients with equivocal appendicitis
  • 17 Oct 2005 DRAXIS Specialty Pharmaceuticals has initiated enrolment a phase II trial with Tc 99m-labelled ciprofloxacin in patients with equivocal appendicitis in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top